Spots Global Cancer Trial Database for pasireotide lar
Every month we try and update this database with for pasireotide lar cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | NCT01794793 | Cushing's Disea... Acromegaly Neuroendocrine ... Pituitary Tumor... Ectopic ACTH Se... Dumping Syndrom... Prostate Cancer Melanoma Negati... Melanoma Negati... | Pasireotide Cabergoline Pasireotide | 18 Years - | RECORDATI GROUP | |
| Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly | NCT02060383 | Cushing's Disea... Acromegaly | Pasireotide s.c... Sitagliptin Liraglutide Insulin Pasireotide LAR Metformin | 18 Years - | Novartis | |
| Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas | NCT00929669 | Gonadotroph Ade... | pasireotide LAR | 18 Years - | University of Pennsylvania | |
| Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors | NCT02749227 | Pituitary Tumor ACTH-producing ... | Pasireotide LAR | 18 Years - 80 Years | Columbia University | |
| Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs) | NCT01364415 | Neuroendocrine ... | Pasireotide LAR | 18 Years - | Novartis | |
| Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET | NCT01374451 | Islet Cell Tumo... | Everolimus Pasireotide LAR | 18 Years - | Novartis | |
| Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly | NCT02060383 | Cushing's Disea... Acromegaly | Pasireotide s.c... Sitagliptin Liraglutide Insulin Pasireotide LAR Metformin | 18 Years - | Novartis | |
| Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease | NCT01374906 | Cushing's Disea... | pasireotide LAR SOM230 LAR 30 m... SOM230 LAR 10 m... | 18 Years - | Novartis | |
| Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin | NCT00958841 | Pancreatic Neop... Pituitary Neopl... Nelson Syndrome Ectopic ACTH Sy... | pasireotide LAR | 18 Years - | Novartis | |
| Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. | NCT01283542 | Non-functioning... | Pasireotide LAR | 18 Years - | Novartis | |
| Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | NCT01794793 | Cushing's Disea... Acromegaly Neuroendocrine ... Pituitary Tumor... Ectopic ACTH Se... Dumping Syndrom... Prostate Cancer Melanoma Negati... Melanoma Negati... | Pasireotide Cabergoline Pasireotide | 18 Years - | RECORDATI GROUP | |
| 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial | NCT01563354 | Neuroendocrine ... | Pasireotide LAR Everolimus Pasireotide LAR... | 18 Years - | Novartis | |
| Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin | NCT00958841 | Pancreatic Neop... Pituitary Neopl... Nelson Syndrome Ectopic ACTH Sy... | pasireotide LAR | 18 Years - | Novartis | |
| 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial | NCT01563354 | Neuroendocrine ... | Pasireotide LAR Everolimus Pasireotide LAR... | 18 Years - | Novartis | |
| Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas | NCT00929669 | Gonadotroph Ade... | pasireotide LAR | 18 Years - | University of Pennsylvania | |
| Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma | NCT01639352 | Hepatocellular ... | SOM230 | 18 Years - | University of Miami |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
